Alexis Gopal is an internal medicine physician and can be reached at Vitality Medicine of New York. She can also be reached on Instagram, Facebook, YouTube, and Pinterest.
CDC / James Gathany
The Center for Infectious Disease Research and Policy (CIDRAP), with support from the Wellcome Trust, a London-based research nonprofit with an eye toward improving flu vaccines, promoting truly revolutionary versions, and ensuring more equitable distribution today released a draft of the Influenza Vaccines Research & Development Roadmap (IVR) for public review and comment.
The IVR project is being led by a steering group of scientists and policymakers and supported by a CIDRAP core team. It aims to develop a globally oriented influenza strategic planning tool to coordinate research and development (R&D), funding, and stakeholder engagement to produce more effective flu vaccines and reduce the impact of future influenza pandemics.
updated: Jan 14 2021, 18:58 ist
The first Covid-19 vaccines have arrived, and the race is on to get them into as many arms as possible as soon as possible. But vaccination rates have fallen frustratingly short of what is needed to turn the tide of this pandemic, which continues to claim thousands of lives every day. The currently authorized vaccines are meant to be given in two doses. To speed things up, some scientists have floated the idea of delaying the second dose, only giving people only a single dose or halving the dose size. UK regulators have prioritized giving as many individuals their first dose of the Pfizer and AstraZeneca vaccines as possible even if that means waiting up to 12 weeks for the second shot. Other countries are also considering changes to their vaccine dosing regimens.